About the Event

The MTPConnect WA Life Sciences Innovation Hub invites you to join the monthly WA MTP Sector Spotlight Series event.

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast in the last week of each month at the Harry Perkins Institute of Medical Research.

Featuring Argenica Therapeutics Limited (ASX:AGN) – developing novel neuroprotective therapeutics to reduce brain damage after stroke

Every 19 minutes someone in Australia will suffer a new stroke. Globally, there were 13 million people who experienced a stroke for the first time in their lives in 2019. When a stroke strikes, it can cause lasting brain damage, long term disability, and even death. Protecting the brain is crucial for improving patient outcomes and recovery.

Based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science, Argenica’s lead candidate ARG-007 aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimise the impact of these conditions and improve patient recovery.

Argenica’s CEO Dr Liz Dallimore and COO Dr Samantha South will discuss the development and commercialisation plans for the company’s novel neuroprotective therapeutic, how it will fit within the current stroke treatment plans, the importance of having a differentiated approach – and clearly communicating all this with investors. They will also take questions from the audience.

About our speakers:

Dr Liz Dallimore – Chief Executive Officer, Argenica Therapeutics Limited

Dr Liz Dallimore is a research & development, innovation, and commercialisation specialist with over 20 years’ experience across Australia and the UK. Prior to joining Argenica Therapeutics, Liz was the Director of the WA Data Science Innovation Hub, tasked with working across WA businesses to establish innovative data science projects.

Dr Dallimore has also held senior management consulting roles with KPMG’s National Director of Research Engagement and Commercialisation and Ernst & Young and PricewaterhouseCoopers.

Dr Dallimore is a co-founder of medical device company Inspiring Holdings, sits on the AusBiotech WA Committee and is a non-executive Director of NERA, the Industry Growth Centre for energy resources. She has a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia and has worked as a neuroscientist at the Australian Neuromuscular Research Institute (now Perron Institute).

In 2020, Dr Dallimore was recognised as one of Western Australia’s Top Women in Tech.

Dr Samantha South – Chief Operating Officer & Executive Director, Argenica Therapeutics Limited

Dr Samantha South has over 13 years’ experience in technology transfer and commercialisation within the medtech/biotech sector as Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation Office at UWA, the University of Queensland (UQ), and Queensland University of Technology (QUTBluebox). Dr South has an extensive background in central nervous system (CNS) research fromt Weill Medical College at Cornell University (NY), UQ and The Garvan Institute. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specialising in CNS animal models.

Dr South was the UWA Director on the boards of UWA spin-out companies, MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Dr South is also the WA AusBiotech Committee Chair and member of the AusMedtech National Advisory Group and SBE Life Sciences Council.

Information:

For any queries, please get in touch with Dr Tracey Wilkinson at tracey.wilkinson@mtpconnect.org.au.

Click here to REGISTER.

---